Navigation Links
Pharmacyclics Announces Subscription Price for Rights Offering
Date:7/15/2009

SUNNYVALE, Calif., July 15 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) (the "Company") announced today that it has set a subscription price of $1.28 per share of its common stock for its previously announced rights offering. An aggregate of approximately 18,750,000 million shares of common stock will be available for purchase in this rights offering for gross proceeds of up to approximately $24 million, less offering expenses, as provided in the prospectus.

The Company previously announced the rights offering will be open to all stockholders of record as of July 15, 2009 (the "Record Date"). Pursuant to the rights offering, holders of the Company's outstanding common stock on the Record Date will receive one non-transferable basic subscription right. Each basic subscription right entitles holders to purchase 0.6808 shares of the Company's common stock at a purchase price of $1.28 per share. Shares of the Company's common stock that are not subscribed for under the basic subscription rights will be offered to each rights holder that exercises its basic subscription rights in full at the same purchase price per share, as provided in the prospectus.

Rights offering materials, including a prospectus and the subscription rights certificates, will be mailed on or about July 16, 2009 to eligible stockholders. The prospectus will contain important information about the rights offering, and stockholders are urged to read the prospectus carefully when available. A registration statement relating to these securities has been filed with the SEC and was declared effective on July 8, 2009.

As previously announced, shareholders wishing to exercise their rights must return their completed certificate along with the applicable funds as directed, on or before July 31, 2009, the
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
2. Pharmacyclics Files Registration Statement for Rights Offering
3. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
4. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
5. Pharmacyclics Secures $5.0 Million in Debt Financing
6. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
7. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
8. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
9. Pharmacyclics Announces It Received Nasdaq Notification
10. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
11. Blue Marble Energy Corp. Announces Successful Close of Series A Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)...en,s University Belfast are developing new sensors... will help in the fight against the threat of terr...l pads to ,swipe, an individual or crime scene to ...ng instrument that can detect the presence of chem...er decisions to be made in response to terrorist t...
(Date:11/18/2009)...Calif., Nov. 18 Masimo...ry(TM) and Measure-Through Motion and Low-Perfusio...e-based Uni.H.A., one of the largest healthcare Gr...signed a multi-year purchasing agreement for "gold...e agreement offers preferred contract pricing to U...
(Date:11/18/2009)...GA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSci...ences product development company that identifies ...er-related products at various stages of developme... nimotuzumab were presented today in a poster at t...r Therapeutics conference in Boston, Massachusetts...
(Date:11/18/2009)...significantly reduces key cardiac enzymes at multi...ted at American Heart Association 2009 Scientific ... Viron Therapeutics Inc., a biotechnology company ...otein therapeutics derived from pathogens, today r...aluating VT-111 (Serp-1), an anti-inflammatory pro...
Breaking Biology Technology:New technology detects chemical weapons in seconds 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4
...scovery at Rensselaer Polytechnic Institute could ... aircraft, watercraft, and automobiles. , Epoxy c... the design of new jets, planes, and other vehicle...ight, which lowers the overall weight of the vehic...t epoxy composites can be brittle, which is detrim...
...etes Care , , IRVINE, Calif., March 26 On March ... its prestigious global diabetes research award. T...vative G1A(TM) Rapid Diabetes Monitoring Index Te...damage caused by excess sugar in the body. , , (P...26/LA89768 ) , , Diabetes is one of the biggest ...
...URAL FUELS INDUSTRIES, INC. (Pink Sheets: VGPR) to...ir rating for the Company to "Fully Compliant", it... OTC Markets categorizes all securities trading ov... inform investors whether an issuer has made adequ...r. Subsequent to NFI,s recent filing, Pink OTC Ma...
Other Biology Technology:Fitter frames: Nanotubes boost structural integrity of composites 2Frost & Sullivan Award Highlights Opportunity for 'Main Street' Biotech 2Pink OTC Markets Moves Natural Fuels Industries to Top Tier 2
(Date:11/20/2009)...ease (COPD), a respiratory disease commonly known ...leading cause of death worldwide. 600 million peo...to find any real treatment or cure, Grace Parraga ... Western Ontario in London, Canada, is using vario... disease. , Parraga is a scientist in the Im...
(Date:11/20/2009)...researchers report that a class of heart medicatio...mful, effect on the heart, depending on their mole...e journal Circulation Research , found that beta-...ptors on the heart muscle offer the most benefit t...he beta-receptors can actually undermine the struc...
(Date:11/19/2009)..., at the end of the last ice age, North America,s ...conic creatures as mammoths, mastodons, camels, ho... precipitous slide to extinction. , And when the...rsity of large animals equaled or surpassed Africa...entirely novel ecosystem emerged as broadleaved tr...
Breaking Biology News(10 mins):Gaining a better picture of lung disease 2Carvedilol shown to have unique characteristics among beta blockers 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Why Do African Americans Fare Worse With Cancer 3F Access and Economics Are Only Part of the Story 4697 1Why Do African Americans Fare Worse With Cancer 3F Access and Economics Are Only Part of the Story 4697 2Why Do African Americans Fare Worse With Cancer 3F Access and Economics Are Only Part of the Story 4697 3New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 1New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 2New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 3New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 4New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 5New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 6Diplomat Specialty Pharmacy 3A Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 50990 1Diplomat Specialty Pharmacy 3A Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 50990 2Diplomat Specialty Pharmacy 3A Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 50990 3
...n human stem cell research, producing embryonic-li...ly speed up the development of treatments for life... The discovery made during a project undertaken wi...anch and the Synthecon Corporation in the United S...with an ethical and reliable source of human stem ...
...-threatening infection in the body, a virus such a...ng, with the cell,s outer membrane. Once inside th...kes over, turning the ,host, cell into a factory t...ll out to invade other cells in the body. , Scient...ith a cell,s membrane, infection of the host cell ...
...he San Francisco VA Medical Center (SFVAMC) and th...ave identified six genes associated with lymphocyt...ative bronchitis (OB), the most common cause of lo...rchers hope their results will lead to an earlier,...or chronic lung rejection, as well as greater unde...
Other Biology News:Insight into the processes of 'positive' and 'negative' learners 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3Researchers identify genes associated with lung transplant rejection 2
...nterferons are cytopathic effect inhibition assays...types include; tissue culture supernatents; serum ...se assays, one unit is defined as the quantity of ...ytopathic effect of viral infection by 50%. All ...
Guanylyltransferase (5 U/l) from Ambion
...Nebulizers are available in two product models - t...se two models is that the 6000AT+ includes a membr...er aerosol for improved detection limits and reduc...tion limits for a range of elements by 10-40 times...
...Nebulizers are available in two product models - t...se two models is that the 6000AT+ includes a membr...er aerosol for improved detection limits and reduc...tion limits for a range of elements by 10-40 times...
Biology Products: